Neonatal Encephalopathy Clinical Trial
— ICONOfficial title:
Investigating Cerebral Oxygenation in the Newborn: An Observational Study Investigating Cerebral Oxygenation in Newborn Infants at High Risk of Brain Injury
NCT number | NCT05588960 |
Other study ID # | AC22120 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 21, 2023 |
Est. completion date | January 2027 |
The goal of this single centre observational study is to use near-infrared spectroscopy (NIRS) monitoring to investigate cerebral oxygenation in two groups of newborn infants who are at high risk of brain injury. The NIRS monitor used in this study will be the Masimo O3 regional oximeter with neonatal sensors. Near-infrared spectroscopy (NIRS) monitoring uses near-infrared light to measure oxygen levels in the brain tissue (cerebral oxygenation). It provides information about blood flow to the brain and the balance between oxygen supply and demand in the brain tissue. It is non-invasive, safe and used routinely to monitor term and premature babies in the neonatal intensive care unit (NICU). This study will recruit two groups of infants admitted to the NICU who are at risk of brain injury in the newborn period, namely: - Term and near-term babies who are undergoing cooling treatment (therapeutic hypothermia) for moderate to severe hypoxic ischaemic encephalopathy (HIE). - Preterm babies who are born extremely prematurely (before 28 weeks of pregnancy). In the term/near-term group, the primary aims of the study are: - To investigate if cerebral oxygenation during and after cooling treatment relates to markers of brain injury detected on detailed brain scans (MRI and MRS scans). - To describe any changes in cerebral oxygenation which occur during and after seizures (fits) in babies undergoing cooling treatment. In the preterm group, the primary aims of the study are: - To investigate if any changes in cerebral oxygenation occurring during skin-to-skin care are different in premature babies with brain injury (bleeding or cysts in the brain seen on ultrasound scan) compared to babies without these changes. - To investigate if cerebral oxygenation at 36 weeks corrected gestational age differs in babies with bronchopulmonary dysplasia (BDP, a chronic lung disease of prematurity) compared to babies without BPD.
Status | Recruiting |
Enrollment | 99 |
Est. completion date | January 2027 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 14 Weeks |
Eligibility | TERM/NEAR-TERM GROUP INCLUSION CRITERIA: 1. Infants born at greater than or equal to 34 weeks gestational age undergoing therapeutic hypothermia as an intervention for moderate to severe neonatal encephalopathy. These infants will meet the following criteria for treatment: - Evidence of intrapartum asphyxia as defined by ANY of the following features: Apgar score of 5 or less at 10 minutes after birth; ongoing need for endotracheal or mask ventilation at 10 minutes after birth; pH <7.00 in cord or baby sample within 60 minutes of birth; base deficit greater than or equal to 16mmol/L in cord or baby sample within 60 minutes of birth. - Moderate or severe encephalopathy, including ALL of the following criteria OR altered consciousness plus seizures: altered consciousness (reduced or absent response to stimulation); abnormal primitive reflexes (weak or absent suck or Moro response); abnormal tone (hypotonia, flaccid). 2. Signed parental consent form. EXCLUSION CRITERIA: 1. Lack of signed parental consent form and/or parental decision not to participate. 2. Infants with life threatening congenital malformations. 3. Infants with encephalopathy caused by differing pathology to hypoxia-ischaemia. PRETERM GROUP INCLUSION CRITERIA: 1. Infants born at less than 28 weeks completed gestation. 2. Signed informed parental consent form for each specific section/sub-study. 3. For skin-to-skin sub-study: considered by responsible clinical team to be eligible for skin-to-skin care as per usual local practice. 4. For BPD sub-study: infants born at less than 28 weeks gestational age surviving to 36 weeks corrected gestational age. Infants with and without a diagnosis of BPD will be recruited to allow for comparison of cerebral oxygenation between these groups. EXCLUSION CRITERIA: 1. Lack of signed parental consent form and/or parental decision not to participate. 2. Decision not to provide active (survival focussed) neonatal management. 3. Infants with life threatening congenital malformation. 4. Infants in whom there is a particularly high level of concerns regarding skin fragility or loss of skin integrity resulting in application of NIRS probe being contraindicated. 5. Infants who are transferred back to local centres will be excluded from the BPD sub-study if transferred back to local centre prior to 36 weeks corrected gestational age and from follow-up data collection due to difficulties achieving acquisition of full data set for babies followed up in health boards outwith NHS Lothian. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Infirmary of Edinburgh | Edinburgh | Lothian |
Lead Sponsor | Collaborator |
---|---|
University of Edinburgh | NHS Lothian, Prism Training and Consultancy, Simpsons Special Care Babies |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Term/Near-Term Group: Primary Outcome 1 | Mean cerebral oxygenation calculated over 1 hour periods at pre-defined time points during therapeutic hypothermia and after completion of rewarming compared to presence/absence of brain injury on magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) performed between 5-15 days after birth.
Brain injury will be defined as: NICHD NRN MRI score of =2A Lactate to n-acetylaspartate peak ratio of >0.39 on MRS |
Birth-15 days | |
Primary | Term/Near-Term Group: Primary Outcome 2 | Maximum change in cerebral oxygenation from baseline occurring during electrical seizures detected on aEEG and cerebral hypoxic burden (expressed in % hours) for any periods of cerebral hypoxia associated with seizures. | Birth-5 days | |
Primary | Preterm Group - Skin-to-skin sub-study: Primary Outcomes | Change in mean cerebral oxygenation (calculated every 5 minutes) and in variability of cerebral oxygenation during a period of skin-to-skin care compared to periods of incubator care before (pre-intervention) and after (post-intervention) skin-to-skin care.
These measures will be compared in infants with and without severe brain injury detected on routine cranial ultrasound scans. Severe brain injury will be defined as: Grade III or IV intraventricular haemorrhage Cystic periventricular leucomalacia |
2.5 hours | |
Primary | Preterm Group - BPD sub-study: Primary Outcomes | Mean cerebral oxygenation measured over a 24-hour period at 36 weeks corrected gestational age and cerebral hypoxic burden (expressed in % hours) of any periods of cerebral hypoxia over this 24-hour epoch.
These measures will be compared in infants with and without a diagnosis of bronchopulmonary dysplasia. Bronchopulmonary dysplasia will be defined as the need for any additional respiratory support (including supplementary oxygen) at 36 weeks corrected gestational age. |
24 hours | |
Secondary | Term/Near-Term Group: Secondary Outcome 1 | Outcome of General Movements Assessment at term and between 12 to 15 weeks post-term age. High-risk patterns will be defined as cramped synchronised pattern (term equivalent age) and absent fidgety movements (12-15 weeks post-term). | Birth-12 to 15 weeks | |
Secondary | Term/Near-Term Group: Secondary Outcome 2 | Outcome at 2 years of age. Adverse outcome will be defined as death or moderate-severe neurodevelopmental disability as follows:
Moderate: Cerebral palsy with GMFCS level 2; Bayley III composite motor/congitive/language score of <85; hearing impairment without need for amplification; persistent seizure disorder. Severe: Cerebral palsy with GMFCS level =3; Bayley III composite motor/cognitive/language score of <70; hearing impairment requiring hearing aids; blindness. |
2 years | |
Secondary | Preterm Group: Secondary Outcome 1 | Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to findings of routine cranial ultrasound scans at:
1 day after birth 2 days after birth 3 days after birth 7 days after birth Term equivalent age |
Birth-max 14 weeks | |
Secondary | Preterm Group: Secondary Outcome 2 | Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to outcomes of General Movements Assessment at term equivalent age and between 12 to 15 weeks post-term age. High-risk patterns will be defined as cramped synchronised pattern (term equivalent age) and absent fidgety movements (12-15 weeks post-term). | Birth-12 to 15 weeks | |
Secondary | Preterm Group: Secondary Outcome 3 | Comparison of mean cerebral oxygenation and cerebral hypoxic burden (expressed in % hours) for the first 72 hours after birth to outcome at 2 years corrected gestational age. Adverse outcome will be defined as death or moderate-severe neurodevelopmental disability as follows:
Moderate: Cerebral palsy with GMFCS level 2; Bayley III composite motor/congitive/language score of <85; hearing impairment without need for amplification; persistent seizure disorder. Severe: Cerebral palsy with GMFCS level =3; Bayley III composite motor/cognitive/language score of <70; hearing impairment requiring hearing aids; blindness. |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05471336 -
Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)
|
N/A | |
Recruiting |
NCT05514340 -
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
|
Phase 2 | |
Recruiting |
NCT04603547 -
Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
|
||
Completed |
NCT01913340 -
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
|
Phase 1/Phase 2 | |
Completed |
NCT00581581 -
CoolCap Followup Study-Coordination of Participating Centers
|
N/A | |
Recruiting |
NCT05772416 -
Neonatal Neurological Examination to Detect Infants at Risk
|
||
Completed |
NCT03122808 -
Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
|
||
Recruiting |
NCT02544100 -
Neonatal Neurologic Intensive Care Network of China
|
||
Completed |
NCT03380013 -
OMT to Improve Feeding After Hypothermia
|
N/A | |
Active, not recruiting |
NCT03409770 -
Optimising the Duration of Cooling in Mild Encephalopathy
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Not yet recruiting |
NCT06098833 -
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia
|
Phase 2 | |
Not yet recruiting |
NCT05756296 -
The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
|
||
Recruiting |
NCT04432662 -
Darbepoetin in Neonatal Encephalopathy Trial
|
Phase 2 | |
Recruiting |
NCT02793999 -
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
|
||
Not yet recruiting |
NCT05889507 -
Cooling in Mild Encephalopathy
|
N/A | |
Recruiting |
NCT05848271 -
Natural History Study of Patients With HPDL Mutations
|
||
Not yet recruiting |
NCT04176471 -
TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy
|
N/A | |
Completed |
NCT01309711 -
Magnetic Resonance Biomarkers in Neonatal Encephalopathy
|
||
Recruiting |
NCT04225975 -
Neonate Cerebral Activity in Immediate Post Partum
|
N/A |